Literature DB >> 7841856

The benzodiazepine withdrawal syndrome.

H Pétursson1.   

Abstract

Physiological dependence on benzodiazepines is accompanied by a withdrawal syndrome which is typically characterized by sleep disturbance, irritability, increased tension and anxiety, panic attacks, hand tremor, sweating, difficulty in concentration, dry wretching and nausea, some weight loss, palpitations, headache, muscular pain and stiffness and a host of perceptual changes. Instances are also reported within the high-dosage category of more serious developments such as seizures and psychotic reactions. Withdrawal from normal dosage benzodiazepine treatment can result in a number of symptomatic patterns. The most common is a short-lived "rebound" anxiety and insomnia, coming on within 1-4 days of discontinuation, depending on the half-life of the particular drug. The second pattern is the full-blown withdrawal syndrome, usually lasting 10-14 days; finally, a third pattern may represent the return of anxiety symptoms which then persist until some form of treatment is instituted. Physiological dependence on benzodiazepines can occur following prolonged treatment with therapeutic doses, but it is not clear what proportion of patients are likely to experience a withdrawal syndrome. It is also unknown to what extent the risk of physiological dependence is dependent upon a minimum duration of exposure or dosage of these drugs. Withdrawal phenomena appear to be more severe following withdrawal from high doses or short-acting benzodiazepines. Dependence on alcohol or other sedatives may increase the risk of benzodiazepine dependence, but it has proved difficult to demonstrate unequivocally differences in the relative abuse potential of individual benzodiazepines.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7841856     DOI: 10.1111/j.1360-0443.1994.tb03743.x

Source DB:  PubMed          Journal:  Addiction        ISSN: 0965-2140            Impact factor:   6.526


  34 in total

1.  Catatonia due to alprazolam withdrawal.

Authors:  Siddharth Iyengar; Charles Bornmann; Farid Abdelmalak; Tulisa LaRocca
Journal:  BMJ Case Rep       Date:  2018-12-14

Review 2.  Drug deprescription-withdrawal risk, prevention, and treatment.

Authors:  Madison K Bangert; Gabriel M Aisenberg
Journal:  Proc (Bayl Univ Med Cent)       Date:  2019-12-20

Review 3.  Metabolic diversity as a reason for unsuccessful detoxification from benzodiazepines: the rationale for serum BZD concentration monitoring.

Authors:  Anna Basińska-Szafrańska
Journal:  Eur J Clin Pharmacol       Date:  2021-01-03       Impact factor: 2.953

Review 4.  Hooked on benzodiazepines: GABAA receptor subtypes and addiction.

Authors:  Kelly R Tan; Uwe Rudolph; Christian Lüscher
Journal:  Trends Neurosci       Date:  2011-02-25       Impact factor: 13.837

5.  Recruitment, Follow-Up and Characteristics of HIV Infected Adults who Use Illicit Drugs in Southern Africa.

Authors:  Marianna K Baum; Adriana Campa; J Bryan Page; Shenghan Lai; Lesedi Tsalaile; Sabrina Sales Martinez; Patricia Burns; O'Dale Williams; Yinghui Li; Erik van Widenfelt; Herman Bussmann; Moyo Sikhulele; Joseph Makhema; Myron Essex; Richard Marlink
Journal:  J Drug Abuse       Date:  2015-12-08

Review 6.  Toxicity of inhaled agents after prolonged administration.

Authors:  Panumart Manatpon; W Andrew Kofke
Journal:  J Clin Monit Comput       Date:  2017-11-02       Impact factor: 2.502

Review 7.  Abuse and dependence liability of benzodiazepine-type drugs: GABA(A) receptor modulation and beyond.

Authors:  Stephanie C Licata; James K Rowlett
Journal:  Pharmacol Biochem Behav       Date:  2008-01-12       Impact factor: 3.533

8.  Development of short-form and screening cutoff point of the Smartphone Addiction Inventory (SPAI-SF).

Authors:  Yu-Hsuan Lin; Yuan-Chien Pan; Sheng-Hsuan Lin; Sue-Huei Chen
Journal:  Int J Methods Psychiatr Res       Date:  2016-09-23       Impact factor: 4.035

9.  Steroid hormone fluctuations and GABA(A)R plasticity.

Authors:  Jamie Maguire; Istvan Mody
Journal:  Psychoneuroendocrinology       Date:  2009-12       Impact factor: 4.905

10.  Short-term treatment with gaboxadol improves sleep maintenance and enhances slow wave sleep in adult patients with primary insomnia.

Authors:  J Lundahl; L Staner; C Staner; H Loft; S Deacon
Journal:  Psychopharmacology (Berl)       Date:  2007-07-27       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.